TOday’s Movers: Shire Plc (LON:SHP) Stock Rating Restated by equity analysts JP Morgan Cazenove; GBX 6100.00 Target Price Indicates 35.41% Potential

Share

Shire Plc (LON:SHP) Rating Reaffirmed

Recently, In analysts note sent to clients and investors on Friday morning, Shire Plc (LON:SHP) shares have had their Overweight Rating has decided to reaffirm by investment analysts at JP Morgan Cazenove, who currently has a GBX 6100.00 target price on firm. This target by JP Morgan Cazenove may imply the possibile upside of 35.41% from the stock close price.

From a total of 11 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 98.66 while the lowest target price is GBX 80.72. The mean of all analyst targets is GBX 89.51 with a 19.76% above today’s (GBX 4545) stock price. Shire PLC was the topic of 78 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on November 30 with “Outperform” rating. Barclays Capital maintained shares with “Overweight” rating and GBX 5700 target share price in a report from a November 3. JP Morgan maintained SHP stock in a recent report from November 17 with “Overweight” rating. Kepler Cheuvreux maintained the rating on November 3. Kepler Cheuvreux has a “Buy” rating and a GBX 5900 price target on shares. Finally, Credit Suisse maintained the stock with “Neutral” rating in a report issued on a November 4.

Approximately 530,764 shares of stock traded hands. Shire PLC (LON:SHP) has declined 12.48% since May 7, 2015 and is downtrending. It has underperformed by 9.70% the S&P500.

TOday’s Movers: Shire Plc (LON:SHP) Stock Rating Restated by equity analysts JP Morgan Cazenove; GBX 6100.00 Target Price Indicates 35.41% Potential

Shire plc is a biopharmaceutical company. The company has a market cap of 26.34 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 13.37 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.

COMMENTS: